CELH
Celsius Holdings, Inc.
CELH has the edge over MAMA overall, supported by stronger valuation and stronger fundamentals.
MAMA
Mama's Creations, Inc.
MAMA has lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MAMA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Strong |
MAMA's revenue, profitability, cash flow and balance sheet are all currently healthy.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over MAMA in the historical PE scenario, which offers more potential upside but is not a forecast.
MAMA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 24x | $4.35 | -67% |
| Forward | 42x | $13.24 | — |
| Fair | 67x | $11.98 | -9.5% |
| Current | 74x | $13.24 | — |
| Expensive | 105x | $18.93 | +43% |
Historical ranges are pointers, not guarantees.
MAMA's PE is in its fair range at 74x. If earnings grow as analysts expect, today's price would be 42x next year's earnings.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
MAMA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for MAMA, with profitability improving.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
MAMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.31 | +75% |
| Q3 2026 | $0.18 | +64% |
| Q2 2026 | $0.15 | +36% |
| Q1 2026 | $0.13 | +44% |
| Q4 2025 | $0.11 | +38% |
| Q3 2025 | $0.11 | -8.3% |
| Q2 2025 | $0.11 | -21% |
| Q1 2025 | $0.09 | -47% |
| Q4 2024 | $0.08 | -58% |
MAMA has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH's revenue has grown year over year for six quarters in a row: $847M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over MAMA on profitability, with a higher operating margin.
MAMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.6M | +55% |
| Q2 2026 | $52.8M | +50% |
| Q1 2026 | $54M | +61% |
| Q4 2025 | $47.3M | +50% |
| Q3 2025 | $35.2M | +24% |
| Q2 2025 | $35.3M | +18% |
| Q1 2025 | $33.6M | +26% |
| Q4 2024 | $31.5M | +10% |
MAMA's revenue has grown year over year for 21 quarters in a row: $55M last quarter, up 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.5% | +0.7 points |
| Q2 2026 | 5% | +0.6 points |
| Q1 2026 | 5.6% | -0.2 points |
| Q4 2025 | 1.7% | -0.1 points |
| Q3 2025 | 4.8% | -0.8 points |
| Q2 2025 | 4.5% | +1.9 points |
| Q1 2025 | 5.7% | -1.6 points |
| Q4 2024 | 1.8% | -7.7 points |
MAMA's operating margin was 5.5% last quarter, up 0.7 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
MAMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6M | +$8.2M |
| Q2 2026 | $4.8M | -12% |
| Q1 2026 | $2.8M | +$3.7M |
| Q4 2025 | $3.7M | +46% |
| Q3 2025 | -$2.2M | +$1.8M |
| Q2 2025 | $5.5M | +119% |
| Q1 2025 | -$930K | -114% |
| Q4 2024 | $2.5M | +129% |
MAMA has the edge over CELH on cash flow, with more consistent year-over-year improvement.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over MAMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
MAMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.6% | +2M shares |
| 1 year | +14% | +5.6M shares |
| 3 years | +21% | +7.8M shares |
| 5 years | +25% | +9.1M shares |
| Available history | +41% | +13.2M shares |
MAMA has 45M diluted shares, up 14% from a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has more cash than debt.
MAMA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -8.9x | Net Cash |
| Q2 2026 | -1.8x | Net Cash |
| Q1 2026 | -1.2x | Net Cash |
| Q4 2025 | -1.7x | Net Cash |
| Q3 2025 | -0.9x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -0.6x | Net Cash |
| Q4 2024 | -0.8x | Net Cash |
MAMA has the edge over CELH on leverage, with a lower net debt burden relative to earnings.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
MAMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 15.0 | Oversold |
MAMA's weekly RSI is 42 (neutral) and its Stochastic is 15 (oversold).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH has the edge over MAMA on valuation relative to its sector.
MAMA PE vs Consumer Defensive Sector
| Metric | MAMA | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 19x | 277% above |
| PE % | 58 | 21 | 37 pts above |
MAMA is trading at 74x earnings, a 277% premium to the Consumer Defensive sector's median of 19x.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
MAMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.1 | 1.1% above |
| 20 week MA | $15.4 | 14% below |
| 50 week MA | $15.1 | 12% below |
| 100 week MA | $11.7 | 14% above |
| 200 week MA | $8.28 | 60% above |
MAMA has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
MAMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $2.57 | $2.13 | -17% |
| 2022 | $2.13 | $1.80 | -15% |
| 2023 | $1.80 | $4.91 | +173% |
| 2024 | $4.91 | $7.74 | +58% |
| 2025 | $7.74 | $13.6 | +75% |
| 2026 YTD | $13.6 | $13.2 | -2.5% |
MAMA has the edge over CELH on returns for 2026, with the stronger performance.